ELLAGIC ACID
Ellagic
acid
is a naturally occurring phenolic constituent in certain fruits and
nuts. Research in the past decade confirms that Ellagic acid
markedly inhibits the ability of other chemicals to cause
mutations in bacteria. Ellagic acid from red raspberries has proven
as an effective antimutagen and anticarcinogen as well as a
inhibitor of cancer.
Ellagic
acid has been found to occur naturally in 46
different foods, with the red raspberry
having been identified as having the highest natural
content.
Ellagic
acid is a phenolic compound found in plants in the form of
hydrolyzable tannins called ellagitannins. Ellagitannins are esters
of glucose with hexahydroxydiphenic acid; when hydrolyzed, they
yield Ellagic acid, the dilactone of hexahydroxydiphenic acid.
Ellagic acid is a very stable compound and is readily absorbed
through the gastrointestinal system in mammals, including humans.
Research
studies on Ellagic acid have been extensive, especially in vitro
studies and studies in laboratory animals. Although yet to prove
conclusively in humans that red raspberries will reduce risk of
cancer or even cause remission of active disease, this research does
represent a substantial body of evidence to support the protective
effects of ellagitannins in humans in combination with other
chemopreventive nutrients.
Berries
are the most common food sources of Ellagic acid. The relative
amount of Ellagic acid in average number of micrograms per gram of
dry weight fruit extract is highest in red raspberries at 1500 mcg,
followed by strawberries at 630 mcg, walnuts at 590 mcg, pecans at
330 mcg, and cranberries at 120 mcg.
Torre,
et al., performed a quantitative evaluation of red raspberries that
was published in the Journal of Food Sciences in 1977:
Ellagic
acid promotes carcinogen detoxification by stimulating the activity
of various isoforms of the enzyme glutathione-S- transferase in
hepatoma (liver cancer).
Ellagic
acid slows the growth of abnormal colon cells in humans, prevents
the development of cells infected with the human papilloma virus (HPV)
linked to cervical cancer, and triggers apoptosis (natural death) of
prostate cancer cells. This apoptotic process may also have
beneficial effects on breast, lung, esophageal, and skin cancer
(melanoma).
Ellagic
acid from raspberries causes apoptosis (normal cell death) of human
cervical cancer cells (human papilloma virus), induces G1 inhibition
of cancer cell division, and prevents destruction of the P53 gene by
cancer cells. P53 is regarded as a safeguard against mutagenic
activity (cancer causing changes) in cervical cells (Nixon,
Narayanan).
Unpublished
research at the Hollings Cancer Center shows that one cup of
raspberries per week will stop prostate cancer growth for a period
of up to one week. Their studies reveal that Ellagic acid from red
raspberries is readily absorbed through the gastrointestinal tract.
Ellagic acid retains its potency after heating, freezing and
concentration processing. So whether consumed fresh, in juices,
fruit spreads, preserves or sorbets, red raspberry has been
recommended as a beneficial part of any healthy diet.
Inhibition
of carcinogenesis by Ellagic acid has been demonstrated in animals
with esophagus, tongue, lung, colon, liver, and skin tumors. Ellagic
acid inhibits the initiation of tumors through a number of
mechanisms, including inhibition of metabolic activation of
carcinogenic compounds (such as polycyclic hydrocarbons, nitroso-containing
chemicals or food preservatives, and aflatoxins) into forms that
induce cell DNA damage.
Ellagic
acid acts as a scavenger to "bind" cancer-causing
chemicals, making them inactive. It inhibits the ability of other
chemicals to cause mutations in bacteria. In addition, Ellagic acid
from red raspberries prevents binding of carcinogens to DNA, and
reduces the incidence of cancer in cultured human cells exposed to
carcinogens. Ellagic acid has been shown to inhibit chemically
induced cancer in the lung, liver, skin and esophagus of rodents,
and TPA-induced tumor promotion in mouse skin (Stoner).
Ellagic
acid elicits a dose-dependent bactericidal effect in H. pylori
cultures, the bacteria thought primarily responsible for the
development of gastric ulcers (Chung).
Ellagic
acid is an effective inhibitor of lung and esophageal tumors in mice
(Stoner).
Ellagic
acid inhibits lipid peroxide and liver hydroxy proline and rectifies
liver pathology in laboratory animal hepatotoxcity induced by carbon
tetrachloride (Thresiamma).
Cancer
can affect DNA by covalent bonding of the carcinogen to the DNA
molecule. Ellagic acid inhibits mutagenesis and carcinogenesis by
forming adducts with DNA, thus masking binding sites to be occupied
by the mutagen or carcinogen (Teel).
Ellagic
acid treatment of preweanling mice before an injection of B(a)P
diol-epoxide caused a 44-75% inhibition in the number of
diol-epoxide-induced lung tumors (Chang).
Ellagic
acid inhibits N-nitrosomethylbenzylamine (NMBA) tumorigenesis in the
esophagus of F-344 rats. Ellagic acid inhibited the development of
both preneoplastic and neoplastic lesions by 25-50% (Daniel and
Stoner).
Ellagic
acid reduced the number of altered foci and the incidence of
hepatocellular neoplasms in rats with liver cancer induced by
N-2-fluorenylacetamide (Tanaka).
There
is clinical evidence that Ellagic acid may inhibit tumors of the
prostate and cervix. Preliminary studies in volunteers indicate
Ellagic acid shows up in cervical tissue after oral ingestion of red
raspberries. One study will evaluate women with atypical squamous
cells of undetermined significance (ASCUS) in which there is neither
treatment nor clinical evaluation available. ASCUS represents as
much as 10% of all Papanicolaou smears in the US and represents
approximately 5 million females. In this population, women infected
with human papillomaviruses (HPV) types 16 and/or 18 are at the
greatest risk of developing cervical cancer at some stage in their
lives. This population represents approximately one million women in
the United States alone, and in India is one of the two major
cancers affecting women.
Ellagic
acids do more than prevent cancer. Berries may also help prevent
heart attacks because they contain a natural form of aspirin called
salicylates. British researchers analyzed the blood of subjects who
were not taking any form of aspirin or drugs containing salicylates.
They found salicylic acid and two related compounds present in
blood, presumably from dietary sources, including raspberries and
blackberries.
Researchers
at the National Center for Health Statistics (NCHS) in Hyattsville,
Maryland established a connection between reduced risk of heart
attack and increased intake of salicylates. They found that during a
10 year period beginning in 1960, when heart attack rates began to
decline, non-aspirin salicylate consumption went up due to
salicylate in processed foods which used a synthetic version to add
flavor and aroma.
Ellagic
acid is pharmacologically active and has been found to control
hemorrhage in animals and in humans, presumably as a result of its
ability to activate Hageman factor. Animal tests suggest that red
raspberry may reduce levels of glucose (blood sugar) in animals, and
therefore may help in the management of diabetes.
Ellagic
acid inhibits lipid peroxidation necrosis of skin flaps, enhancing
preservation of grafting procedures (Ashoori).
Ellagic
acid has a marked inhibitory effect on acid secretion and the
occurrence of stress-induced gastric lesions (Murakami).
Ellagitannins
are also believed by herbalists to be effective in treating
diarrhea, nausea, vomiting and morning sickness in pregnancy.
Herbalists do not, however, recommend you use red raspberry for this
purpose at home even though red raspberry leaves are included in
several herbal pregnancy formulas sold in the United States for
women with a history of miscarriage or difficult pregnancy for the
purpose of regulating uterine contractions, morning sickness, hot
flashes, diarrhea (use weak tea for infants), and for reducing
excessive menstrual flow. The herb is also used as a gargle for sore
throats.
Consuming
one cup (150 grams) of red raspberries per day prevents the
development of prostate cancer cells in unpublished studies. Most
extract formulas recommend from 500-2000 mg of ellagitannins per
day. The amount of Ellagic acid found in red raspberries is 1500
micrograms per gram of dry weight. If one cup contains 150 grams by
dry weight, then each cup of red raspberries would average 225 mg of
Ellagic acids as well as up to 90 mg of anthocyanidins and less than
40 mg of other polyphenols including flavanols. As with many herbal
remedies, suggested use and precise dose response relationships have
not been established for ellagitannins extracted from red
raspberries.
Selected References
Ahn
D et al. The effects of dietary ellagic acid on rat hepatic and
esophageal mucosal cytochromes P450 and phase II enzymes.
Carcinogenesis 17:821-828, 1996.
Ayrton
AD et al. Antimutagenicity of ellagic acid towards the food mutagen
IQ: investigation into possible mechanisms of action. Food Chem
Toxicol 30(4):289-95, 1992.
Barch
DH et al. Ellagic Acid Induces NAD(P)H:Quinone Reductase Through
Activation of the Antioxidant Regulatory Element of the Rat
NAD(P)H:Quinone Reductase Gene. Carcinogenesis 15:2065-2068, 1994.
Bhargava
UC et al. The mechanism of blood pressure depression by ellagic
acid. Proc Soc Exp Biol Med 132(2):754-6, 1969.
Castonguay
A et al. Antitumorigenic and antipromoting activities of ellagic
acid, ellagitannins and oligomeric anthocyanin and procyanidin. Int
J Oncology 10, 367-373, 1997.
Constantinou
A et al. The dietary anticancer agent ellagic acid is a potent
inhibitor of DNA topoisomerases in vitro. Nutr Cancer 23(2):121-30,
1995.
Daniel
EM et al. The effects of ellagic acid and 13-cis-retinoic acid on N-
nitrosobenzylmethylamine-induced esophagal tumorigenesis in rats.
Cancer Lett 56:117-124, 1991.
Lesca
P. Protective effects of ellagic acid and other plant phenols on
benzo(a)pyrene-induced neoplasia in mice. Carcinogenesis
4:1651-1653, 1983.
Muktar
H et al. Ellagic acid: A potent naturally occurring inhibitor of
benzo[a]pyrene metabolism and its subsequent glucuronidation,
sulfation and covalent binding to DNA in cultured BALA/c mouse
keratinocytes. Carcinogenesis 5: 1565-1571, 1984. Nixon DW.
Alternative and complementary therapies in oncology care. J Clin
Oncol 17(11 Suppl):35-7, 1999. Nixon DW. Prostate cancer and
nutrition. JSC Med Assoc 96(2): 85-6, 2000. Nixon DW. Preventive
medicine in the year 2000. Prev Med 30(1): 1-2, 2000.)
Perchellet
JP et al. Antitumor-promoting activities of tannic acid, ellagic
acid, and several gallic acid derivatives in mouse skin. Basic Life
Sci 59:783-801, 1992.
Rao
CV et al. Chemoprevention of colon carcinogenesis by dietary
administration of Piroxicam, Difluoromethylornithine,
16beta-Fluoro-5- androsten-17-one, and Ellagic Acid individually and
in combination. Cancer Research 51: 4528-4534, 1991.
Rommel
A et al. Red raspberry phenolic. Influences of processing, variety
and environmental factors. In: Ho C-T, Lee CY, Huan M-T Eds.
Phenolic Compounds in Food and Their Effects on Health I. Analysis,
Occurrence & Chemistry. Washington DC. American Chemical
Society. 259-286, 1992.
Rossi
M et al. The crystal and molecular structure of ellagic acid
dihydrate: a dietary anti-cancer agent. Carcinogenesis 12:2227-32,
1991.
Singletary
K et al. Ellagic acid effects on the carcinogenicity, DNA-binding
and metabolism of 7,12-dimethylbenz[a}anthracene (DMBA). In Vivo 3:
173-176, 1989.
Smart
RC et al. Effect of ellagic acid and 3-O-decylellagic acid on the
formation of benzo[a]pyrene-derived DNA adducts in vivo and on the
tumorigenicity of 3-methylcholanthrene in mice. Carcinogenesis
7(10):1669-75, 1986.
Tanaka
T et al. Inhibitory effect of ellagic acid on N-2-fluoenylacetamide-
induced liver carcinogenesis in male AC1/N rats. Jpn J Cancer Res
(Gann) 79:1297-1303, 1988.
Tanaka
T et al. Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue
carcinogenesis by the naturally occurring plant phenolics caffeic,
ellagic, chlorogenic and ferulic acids. Carcinogenesis
x14(7):1321-5, 1993.
Teel
RW. Ellagic acid binding to DNA as a possible mechanism for its
antimutagenic and anticarcinogenic action. Cancer Lett 30(3):329-36,
1986.
|